A special place for IL-6 in LC treatment, specifically its inhibition, is in K-ras-positive non-small-cell lung cancer (NSCLC), as patients with a positive K-ras LC have significant inflammation in tumor stroma [13]. Here, IL6 is linked to neoplasm.